BMRN240920P87500
- 1.88
- -0.12-6.00%
Biomarin Pharmaceutical Newsroom
BioMarin Pharmaceutical Announces Executive Leadership Transition
Evercore Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $115
Evercore ISI Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
BioMarin Appoints New Business Chief and R&D Head
Express News | Biomarin Announces New R&D and Business Development Leadership
Stifel Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $115
S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead
Express News | Biomarin Pharmaceutical Inc : Stifel Raises Target Price to $115 From $112
BioMarin Announces New R&D and Business Development Leadership
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Express News | BioMarin Pharmaceutical Shares Are Trading Higher After Bernstein Upgraded the Stock to Outperform, Raising Voxzogo 2032 Sales Estimates and Saying It Expects Management to Lay Out a Margin Expansion Path
Express News | Biomarin Pharmaceutical Shares up 2.4% Premarket After Bernstein Raises to Outperform From Market-Perform
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Biomarin Pharmaceutical Analyst Ratings
Bernstein Upgrades Biomarin Pharmaceutical(BMRN.US) to Buy Rating, Raises Target Price to $110
Express News | Biomarin Pharmaceutical Inc : Bernstein Raises Target Price to $110 From $94
Express News | Biomarin Pharmaceutical Inc : Bernstein Raises to Outperform From Market-Perform
BioMarin to Host 2024 Investor Day on September 4th in New York
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 44% Undervalued